Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospita... by Sikiru Olatunji Usman, Ibrahim Adekunle Oreagba, Akinwumi Akinyinka Akinyede, Esther Oluwatoyin Agbaje, Moshood Olusola Akinleye, Adaobi Goodness Onwujuobi, Chioma Ken-Owotor, Olatunbosun Adeuja, Tosin Ogunfowokan, Segun Kogbe, Emmanuel Tope Owolabi, Hannah Adeniji, Abdul Wasiu Busari, Olayinka Olayiwola Hassan, Ganiu Abideen, Alani Sulaimon Akanmu

“…Patients living with HIV in malarial endemic regions may experience clinically significant drug interaction between antiretroviral and antimalarial drugs. …”
Get full text

Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population by Anura V Kurpad, Disha Sharma, KM Venkat Narayan, Ambily Sivadas, Arpita Mukhopadhyay, Greg Gibson, Abhinav Jain, S Sahana, Bani Jolly, Rahul C Bhoyar, Mohamed Imran, Vigneshwar Senthivel, Mohit Kumar Divakar, Anushree Mishra, Sridhar Sivasubbu, Vinod Scaria

“…The recent availability of large-scale whole genomes from the Indian population provides a unique opportunity to generate a population-specific map of NIAD-associated PGx variants.Research design and methods We mined 1029 Indian whole genomes for PGx variants, drug–drug interaction (DDI) and drug–drug–gene interactions (DDGI) associated with 44 NIADs. …”
Get full text

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma by Elisabetta Vergani, Giovanni L. Beretta, Mariachiara Aloisi, Matteo Costantino, Cristina Corno, Simona Frigerio, Stella Tinelli, Matteo Dugo, Felice Maria Accattatis, Agnese Granata, Lorenzo Arnaboldi, Monica Rodolfo, Paola Perego, Laura Gatti

“…Molecular targeting of ACAT2 or pharmacological inhibition of SOAT by avasimibe showed antiproliferative effects in melanoma cell lines and a synergistic drug interaction with PLX4032, an effect associated to increased ferroptosis. …”
Get full text

Development, Characterization and Cell Viability Inhibition of PVA Spheres Loaded with Doxorubicin and 4′-Amino-1-Naphthyl-Chalcone (D14) for Osteosarcoma by Viviane Seba, Gabriel Goetten de Lima, Bruno L. Pereira, Gabriel Silva, Luiza Steffens Reinhardt, Pablo Ricardo Arantes, Bor Shin Chee, Mariana Bastos dos Santos, Suzelei C. França, Luis Octavio Regasini, Ana Lúcia Fachin, Zhi Cao, Michael J. D. Nugent, Mozart Marins

“…The co-delivery showed a cytotoxic effect 2.6-fold greater than doxorubicin alone, revealing a significant synergistic effect with a coefficient of drug interaction (CDI) of 0.49. The obtained results suggest this developed PVA sphere as a potential dual-drug delivery system that could be used for the prominent synergistic anticancer activity of co-delivering D14 and doxorubicin, providing a new potential strategy for improved osteosarcoma treatment.…”
Get full text

Graphene Oxide-Linezolid Combination as Potential New Anti-Tuberculosis Treatment by Flavio De Maio, Valentina Palmieri, Giulia Santarelli, Giordano Perini, Alessandro Salustri, Ivana Palucci, Michela Sali, Jacopo Gervasoni, Aniello Primiano, Gabriele Ciasca, Maurizio Sanguinetti, Marco De Spirito, Giovanni Delogu, Massimiliano Papi

“…In the same way, changing cell–drug interaction by nanotechnology could represent an innovative strategy to fight infectious diseases. …”
Get full text

ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1 by Kai Wang, Xun Qiu, Zhensheng Zhang, Hanzhi Xu, Yawen Tan, Renyi Su, Fengqiang Gao, Jianyong Zhuo, Wangyao Li, Zhengxing Lian, Hong He, Xiao Xu

“…ATRA inhibited the progression of HCC and sensitized HCC response to Sorafenib by downregulation of PAK1, as shown by the calculated coefficient of drug interaction and the data obtained from xenograft models. …”
Get full text

To what extent do people living with HIV, people on pre-exposure prophylaxis, doctors and pharmacists endorse 90-day dispensing of antiretroviral therapy in France? by Christine Jacomet, Émilie Goncalves, Céline Lambert, Didier Chedorge, Sylvia Puglièse-Wehrlen, Éric Billaud, David Zucman, Anne Simon, Cédric Arvieux, Hervé Trout, Bruno Laurandin, René Maarek, Isabelle Raymond, Pascal Puglièse, Julie Langlois, Agnès Certain

“…Moreover, pharmacists thought it would be necessary to commit regulatory resources and a better follow-up on adherence and drug-drug interactions.…”
Get full text

Knowledge, Attitude, and Perception of Health Care Providers Providing Medication Therapy Management (MTM) Services to Older Adults in Saudi Arabia by Fawaz M. Alotaibi, Zainab M. Bukhamsin, Alanoud Nasser Alsharafaa, Ibrahim M. Asiri, Sawsan M. Kurdi, Dhafer M. Alshayban, Mohammed M. Alsultan, Bassem A. Almalki, Wafa Ali Alzlaiq, Mansour M. Alotaibi

“…Introduction: Medication Therapy Management (MTM) is identified as a group of services provided to the patient in order to optimize the medication use in order to mitigate adverse drug reactions (ADRs), drug–drug interaction (DDI), and polypharmacy. Elderly populations above 60 years old are at high risk for Medication-related Problems (MRPs) due to several factors. …”
Get full text

Effects of <i>Catha edulis</i> (Khat) on the Pharmacokinetics of Metformin in Diabetic Rats Using UPLC/MS/MS Analysis and Its Impact on Hepatic CYP450 Enzymes by Ali S. Alqahtani, Mohammad Khalid Parvez, Abdulaziz M. Alqahtani, Omer I. Fantoukh, Rashed N. Herqash, Ehab M. Elzayat, Fahd A. Nasr, Essam Ezzeldin, Mousallam M. Almousallam, Mohammad Raish

“…In this study, our aim was to investigate the possibility of an herb–drug interaction between KT extract and metformin (MT) by exploring the effect of KT on the in vivo pharmacokinetics of MT in diabetic Wistar albino rats and monitoring blood glucose levels through time intervals, comparing when MT was given alone and co-administered with KT. …”
Get full text

Chitosan Nanoparticles as Oral Drug Carriers by Omar Rodrigo Guadarrama-Escobar, Pablo Serrano-Castañeda, Ericka Anguiano-Almazán, Alma Vázquez-Durán, Ma. Concepción Peña-Juárez, Ricardo Vera-Graziano, Miriam Isabel Morales-Florido, Betsabe Rodriguez-Perez, Isabel Marlen Rodriguez-Cruz, Jorge Esteban Miranda-Calderón, José Juan Escobar-Chávez

“…Chitosan has been shown to have an extensive variability of properties and roles in the pharmaceutical and health fields; of its most important properties are the ability to encapsulate and transport drugs within the body and enhance the drug interaction with the target cells, which improves the efficacy of the encapsulated drugs. …”
Get full text

Cytotoxic effects of combined cisplatin and clinacanthus nutans in mda-mb-231 and MDA-MB-468 triple negative breast cancer cells by Abu Bakar, Nur Fitriyani Afiqah

“…Three different treatments were studied, Cisplatin at 0-15.23 µg/mL, C. nutans at 0-50 µg/mL and combined treatment of 3.05 µg/mL cisplatin with C. nutans at 0-50 µg/mL. Next, a drug interaction study was done using isobologram-combination index analysis. …”
Get full text

Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma by Ziyue Gu, Chaoji Shi, Jiayi Li, Yong Han, Bao Sun, Wuchang Zhang, Jing Wu, Guoyu Zhou, Weimin Ye, Jiang Li, Zhiyuan Zhang, Rong Zhou

“…The high-throughput combination drug screening provided a comprehensive palbociclib-based drug-drug interaction dataset, whereas significant synergistic effects were observed when palbociclib was combined with multiple agents, including inhibitors of the PI3K, EGFR, and MEK pathways. …”
Get full text

A randomized controlled pilot study of add-on therapy of CIM-MEG19 (standardized Andrographis paniculata formulation) in mild to moderate COVID-19 by Karuna Shanker, Hrishikesh Rangnekar, Asmita Wele, Pravin Soni, Pranesh Gaikwad, Anirban Pal, Dnyaneshwar U. Bawankule, Debabrata Chanda

“…Purpose: The study aimed to assess the efficacy and safety of the CIM-MEG19 (standardized A. paniculata extract formulation), a proprietary Ayurvedic medicine in the COVID-19 management, clinical recovery, and outcomes in terms of hospitalization days as well as any sign of severity due to drug-drug interaction between CIM-MEG19 TM and standard of care (SoC). …”
Get full text

Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation by Kyaw Zwar Myint, Brinda Balasubramanian, Simran Venkatraman, Suchada Phimsen, Supisara Sripramote, Jeranan Jantra, Chaiwat Choeiphuk, Somkit Mingphruedhi, Paramin Muangkaew, Narongsak Rungsakulkij, Pongsatorn Tangtawee, Wikran Suragul, Watoo Vassanasiri Farquharson, Kanokpan Wongprasert, Somchai Chutipongtanate, Pimtip Sanvarinda, Marisa Ponpuak, Naravat Poungvarin, Tavan Janvilisri, Tuangporn Suthiphongchai, Kiren Yacqub-Usman, Anna M. Grabowska, David O. Bates, Rutaiwan Tohtong

“…Furthermore, the drug interaction relationship between ceritinib and cisplatin was determined using a ZIP synergy score. …”
Get full text

Comparison of medical documentation between pharmacist-led anticoagulation clinics and physician-led anticoagulation clinics: A retrospective study by Mansour Almuqbil, Haya Alturki, Lobna Al Juffali, Nourah Al-otaibi, Nada Awaad, Nora Alkhudair, Abdullah M. Alhammad, Bashayr Alsuwayni, Sara Alrouwaijeh, Mohammad Aljawadi, Abdulaziz Alhossan, Syed Mohammed Basheeruddin Asdaq

“…The examination of the variables considered in the study revealed that physicians had significantly less drug-drug interaction documentation (17 vs. 71 times) or drug-food interaction documentation (23 vs. 71 times) than pharmacists. …”
Get full text

CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder by Sheila T. Nagamatsu, Sheila T. Nagamatsu, Sheila T. Nagamatsu, Gregory Rompala, Yasmin L. Hurd, Diana L. Núñez-Rios, Diana L. Núñez-Rios, Diana L. Núñez-Rios, Janitza L. Montalvo-Ortiz, Janitza L. Montalvo-Ortiz, Janitza L. Montalvo-Ortiz, Traumatic Stress Brain Research Group, Victor E. Alvarez, David Benedek, Alicia Che, Dianne A. Cruz, David A. Davis, Matthew J. Girgenti, Ellen Hoffman, Paul E. Holtzheimer, Bertrand R. Huber, Alfred Kaye, John H. Krystal, Adam T. Labadorf, Terence M. Keane, Mark W. Logue, Ann McKee, Brian Marx, Deborah Mash, Mark W. Miller, Crystal Noller, JM-O, William K. Scott, Paula Schnurr, Thor Stein, Robert Ursano, Douglas E. Williamson, Erika J. Wolf, Keith A. Young

“…KEGG enrichment analysis identified axon guidance and glutamatergic synapse (FDR 9E-4–2.1E-2). Drug interaction analysis found 3,420 interactions between the annotated genes and drugs, identifying interactions with 15 opioid-related drugs, including lofexidine and tizanidine, both previously used for the treatment of OUD-related symptoms.ConclusionOur findings suggest a role of mCpHs for OUD in cortical neurons and reveal important biological pathways and drug targets associated with the disorder.…”
Get full text

Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus by Valeria Raparelli, Malik Elharram, Cristiano S. Moura, Michal Abrahamowicz, Sasha Bernatsky, Hassan Behlouli, Louise Pilote

“…Compared with sulfonylureas, hazard ratios (HRs) for cardiovascular events were lower with GLP‐1RA (adjusted HR‐women: 0.57, 95% CI: 0.48–0.68; aHR‐men: 0.82, 0.71–0.95), dipeptidyl peptidase‐4 inhibitors (aHR‐women: 0.83, 0.77–0.89; aHR‐men: 0.85, 0.79–0.91) and SGLT‐2i (aHR‐women: 0.58, 0.46–0.74; aHR‐men: 0.69, 0.57–0.83). A sex‐by‐drug interaction was statistically significant only for GLP‐1RA (P=0.002), suggesting greater cardiovascular effectiveness in women. …”
Get full text

Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection by Tafadzwa Dzinamarira, Mazen Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A. Rabaan, Amal H. Alfaraj, Bashayer M. AlShehail, Nouf Alotaibi, Shams M. AlShehail, Mohd Imran

“…The associated diseases make HIV treatment complex and warrant drug interaction studies (drug–drug, drug–food, and drug–disease interaction). …”
Get full text

Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or... by Nicolas Hohmann, Martin Ronald Sprick, Moritz Pohl, Azaz Ahmed, Jürgen Burhenne, Marietta Kirchner, Lucian Le Cornet, Markus Kratzmann, Jacek Hajda, Albrecht Stenzinger, Karen Steindorf, Stefan Delorme, Heinz‐Peter Schlemmer, Sabine Riethdorf, Ron vanSchaik, Klaus Pantel, Jens Siveke, Thomas Seufferlein, Dirk Jäger, Walter E. Haefeli, Andreas Trumpp, Christoph Springfeld

“…Although the doses of gemcitabine (1000 mg/m2) and cobicistat (150 mg) are fixed, three dose levels of nab‐paclitaxel (75, 100, and 125 mg/m2) will be explored to account for a potential PK drug interaction. After the dose escalation phase, we will set the recommended dose for expansion (RDE) and treat up to nine patients in an expansion part of the trial. …”
Get full text

Intracarotid Infusion of Redox-Active Manganese Porphyrin, MnTnBuOE-2-PyP⁵⁺, following Reperfusion Improves Long-Term, 28-Day Post-Stroke Outcomes in Rats by Xuan Li, Weina Duan, Li Du, Dongmei Chu, Peng Wang, Zhong Yang, Xingguang Qu, Zhenxing Yang, Ines Batinic-Haberle, Ivan Spasojevic, David S. Warner, James D. Crapo, Miriam M. Treggiari, Huaxin Sheng

“…No vascular wall damage and blood–brain barrier permeability changes were detected after the BMX-001 infusion. There was no drug interaction between BMX-001 and t-PA. Intracarotid BMX-001 infusion was safe, and it significantly improved stroke outcomes in rats. …”
Get full text